Edition:
United Kingdom

Aclaris Therapeutics Inc (ACRS.OQ)

ACRS.OQ on NASDAQ Stock Exchange Global Select Market

6.83USD
25 Apr 2019
Change (% chg)

-- (--)
Prev Close
$6.83
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
188,228
52-wk High
$21.31
52-wk Low
$5.04

Latest Key Developments (Source: Significant Developments)

Aclaris Therapeutics QTRLY Loss Per Share $0.99
Monday, 18 Mar 2019 

March 18 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL AND COMMERCIAL DEVELOPMENTS.Q4 REVENUE $3.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $3.5 MILLION.INITIATES FINANCIAL GUIDANCE FOR FULL YEAR 2019.EXPECTS 2019 GAAP RESEARCH AND DEVELOPMENT (RESEARCH AND DEVELOPMENT) EXPENSES TO BE IN RANGE OF $61 TO $64 MILLION.EXPECTS 2019 GAAP SALES AND MARKETING (S&M) EXPENSES TO BE IN RANGE OF $37 TO $40 MILLION.EXPECTS 2019 GAAP GENERAL AND ADMINISTRATIVE (G&A) EXPENSES TO BE IN RANGE OF $29 TO $31 MILLION.QTRLY LOSS PER SHARE $0.99.  Full Article

Aclaris Therapeutics Q3 Loss Per Share $1.06
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL AND COMMERCIAL DEVELOPMENTS.Q3 LOSS PER SHARE $1.06.Q3 EARNINGS PER SHARE VIEW $-1.33 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE $1.6 MILLION VERSUS I/B/E/S VIEW $1.8 MILLION.UPDATED ITS EXPECTED FY 2018 GAAP RESEARCH AND DEVELOPMENT EXPENSES TO BE IN RANGE OF $62 MILLION TO $64 MILLION.UPDATED EXPECTED FY 2018 GAAP SELLING, GENERAL AND ADMINISTRATIVE EXPENSES TO BE IN RANGE OF $77 MILLION TO $79 MILLION.  Full Article

Cipher Pharmaceuticals Acquires Canadian Rights To U.S. FDA-Approved A 101 40% Topical Solution
Friday, 6 Apr 2018 

April 6 (Reuters) - Cipher Pharmaceuticals::CIPHER PHARMACEUTICALS ACQUIRES EXCLUSIVE CANADIAN RIGHTS TO U.S. FDA-APPROVED A-101 40% TOPICAL SOLUTION FROM ACLARIS THERAPEUTICS.CIPHER PHARMACEUTICALS INC - ACLARIS WILL RECEIVE AN UPFRONT PAYMENT OF US$1.0 MLN .  Full Article

Aclaris Says Primary, Secondary, And Exploratory Endpoints Of Phase 2 Trial of A-101 45% Met
Monday, 19 Mar 2018 

March 19 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS ANNOUNCES POSITIVE UPDATE ON PHASE 2 RESULTS AFTER A 3-MONTH FOLLOW-UP OF A-101 45% TOPICAL SOLUTION FOR POTENTIAL TREATMENT OF COMMON WARTS.ACLARIS THERAPEUTICS INC - PRIMARY, SECONDARY, AND EXPLORATORY ENDPOINTS OF PHASE 2 TRIAL MET DURING 8-WEEK TREATMENT PERIOD.ACLARIS THERAPEUTICS - AFTER TREATMENT COMPLETED, GREATER IMPROVEMENT VERSUS. PLACEBO OBSERVED IN 3-MONTH POST-TREATMENT FOLLOW-UP EVALUATION IN TRIAL.ACLARIS THERAPEUTICS INC - THERE WERE NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS AMONG SUBJECTS TREATED WITH A-101 45%.ACLARIS THERAPEUTICS INC - A-101 45% WAS GENERALLY WELL TOLERATED THROUGH VISIT 13.  Full Article

Aclaris Therapeutics Q4 Revenue $1.0 Mln
Monday, 12 Mar 2018 

March 12 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL AND COMMERCIAL DEVELOPMENTS.Q4 REVENUE $1.0 MILLION.Q4 REVENUE VIEW $520,000 -- THOMSON REUTERS I/B/E/S.AS OF DECEMBER 31, 2017, HAD AGGREGATE CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $208.9 MILLION.ACLARIS THERAPEUTICS - EXPECTS CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF DEC 31, 2017 WILL BE SUFFICIENT TO FUND OPERATIONS INTO H2 2019.  Full Article

Aclaris Therapeutics' A-101 45% Topical Solution Meets Primary, All Secondary Endpoints In Two Phase 2 Clinical Trials For Common Warts
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN TWO PHASE 2 CLINICAL TRIALS FOR COMMON WARTS.ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN TWO PHASE 2 CLINICAL TRIALS FOR COMMON WARTS.ACLARIS THERAPEUTICS - ‍POSITIVE RESULTS FROM 2 PHASE 2 CLINICAL TRIALS,WART-202,WART-203 OF A-101 45% TOPICAL SOLUTION,FOR TREATMENT OF COMMON WARTS​.ACLARIS - ‍A-101 45% MET ALL PRIMARY,SECONDARY ENDPOINTS OF EACH TRIAL, ACHIEVING CLINICALLY,STATISTICALLY SIGNIFICANT CLEARANCE OF COMMON WARTS​.  Full Article

Aclaris Therapeutics Receives FDA Approval For Eskata For Treatment Of Raised SKs
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS RECEIVES FDA APPROVAL FOR ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W) FOR THE TREATMENT OF RAISED SEBORRHEIC KERATOSES (SKS).ACLARIS THERAPEUTICS RECEIVES FDA APPROVAL FOR ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W) FOR THE TREATMENT OF RAISED SEBORRHEIC KERATOSES (SKS).ACLARIS THERAPEUTICS - FDA APPROVAL OF ESKATA BASED ON 2 PIVOTAL PHASE 3 TRIALS THAT SHOWED SAFETY & EFFICACY OF ESKATA FOR TREATMENT OF RAISED SKS.  Full Article

Aclaris Therapeutics says qtrly loss per share $0.63
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Aclaris Therapeutics Inc -:Aclaris Therapeutics reports third quarter 2017 financial results.Aclaris Therapeutics Inc - qtrly loss per share $0.63.Aclaris Therapeutics Inc - qtrly revenue of $684,000.Aclaris Therapeutics Inc- ‍cash burn for 2017 is now estimated to be in range of $56 million to $59 million​.Aclaris Therapeutics Inc- ‍research and development expenses for 2017 are now estimated to be in range of $39 million to $42 million​.  Full Article

Aclaris Therapeutics announces publication of phase 2 trial data of A-101 for treatment of facial seborrheic keratosis
Tuesday, 19 Sep 2017 

Sept 19 (Reuters) - Aclaris Therapeutics Inc :Aclaris Therapeutics announces publication of data from phase 2 clinical trial of A-101 topical solution for treatment of facial seborrheic keratosis.Aclaris Therapeutics Inc - ‍ in trial, A-101 achieved statistical significance in clearing SK lesions on face in a dose-related fashion​.Aclaris Therapeutics Inc - ‍ FDA's Prescription Drug User Fee Act Action date for new drug application is December 24, 2017​.Aclaris Therapeutics Inc - ‍ A-101 was well tolerated at both concentrations studied​.Aclaris Therapeutics Inc - ‍there were no treatment-related adverse events among patients treated with A-101​.  Full Article

Vivo Ventures VII LLC reports 9.5 pct stake in Aclaris Therapeutics
Monday, 14 Aug 2017 

Aug 14 (Reuters) - Aclaris Therapeutics Inc :Vivo Ventures VII LLC reports 9.5 percent stake in Aclaris Therapeutics Inc as of March 15, 2017 - SEC filing.Vivo Ventures VII LLC had previously reported 13.34 percent in Aclaris Therapeutics Inc as of February 28, 2017.  Full Article